SCHEDULE: Casdin Capital Boosts BioLife Solutions Stake to 14%

Casdin Capital and its affiliates have increased their beneficial ownership in BioLife Solutions, Inc. to 14.0% through a recent acquisition of 500,000 shares.

Summary

• Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC, and Eli Casdin (collectively, 'Reporting Persons') have filed an Amendment No. 5 to Schedule 13D regarding BioLife Solutions, Inc.
• The Reporting Persons now beneficially own an aggregate of 6,707,165 shares of BioLife Solutions, Inc. Common Stock.
• This ownership represents 14.0% of the outstanding shares, calculated based on 47,905,265 shares outstanding as of July 31, 2025.
• The shares were acquired for investment purposes, funded by the working capital of Casdin Partners Master Fund, L.P.
• A recent transaction on August 15, 2025, involved the acquisition of 500,000 shares at a price of $24.40 per share.
• The Reporting Persons reserve the right to engage with the Issuer's management and Board of Directors, as well as other significant shareholders, to explore alternatives to maximize shareholder value.

Sentiment

Score: 7

Explanation: The increase in beneficial ownership by Casdin Capital, a specialized life sciences investor, to a significant 14.0% stake, coupled with their stated intent to engage with management to maximize shareholder value, suggests a strong vote of confidence and potential for strategic oversight. This is generally viewed positively by the market.

Positives

• A significant institutional investor, Casdin Capital, has increased its stake, indicating confidence in BioLife Solutions' future prospects.
• The acquisition of 500,000 shares at $24.40 per share on August 15, 2025, demonstrates a recent, substantial investment at a specific valuation.
• Reporting Persons explicitly state their purpose is investment and reserve the right to engage with management to maximize shareholder value, suggesting potential for active oversight and strategic improvements.

Future Outlook

The Reporting Persons have acquired their shares for investment purposes and reserve the right to engage with the Issuer's management and Board of Directors, as well as other significant shareholders, to explore alternatives to maximize shareholder value. They may also dispose of or enter into other transactions with the shares they beneficially own.

Management Comments

• The Reporting Persons have acquired their Shares of the Issuer for investment.
• The Reporting Persons, however, reserve the right, at a later date, to effect one or more of such changes and may dispose of or enter into other transactions in the shares they may be deemed to beneficially own.
• The Reporting Persons have been and may continue to be in contact with members of the Issuer's management, the Issuer's Board of Directors, other significant shareholders and others regarding alternatives that the Issuer could employ to maximize shareholder value.
• The Reporting Persons further reserve the right to act in concert with any other shareholders of the Issuer, or other persons, for a common purpose should it determine to do so, and/or to recommend courses of action to management and the shareholders of the Issuer.

Industry Context

This filing indicates a significant institutional investor, Casdin Capital, a specialist in life sciences and biotechnology, is increasing its stake in BioLife Solutions. This suggests a belief in the long-term value or strategic potential of BioLife Solutions within the broader biotechnology and cell/gene therapy tools industry. Such an increase in ownership by a sector-focused fund can be seen as a positive signal for the company's prospects, potentially highlighting its position in a growing market.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if Casdin Capital's engagement leads to strategic improvements. Increased institutional ownership may also lend credibility.
• Management/Board: May face increased scrutiny or pressure from a significant activist investor to implement strategies for value maximization.

Next Steps

• Reporting Persons may engage in further discussions with BioLife Solutions' management and Board of Directors.
• Reporting Persons may propose or effect changes to the Issuer's corporate structure, capitalization, or operating policies in the future.
• Reporting Persons may dispose of or enter into other transactions with their shares.
• Reporting Persons may act in concert with other shareholders for a common purpose.

Key Dates

Recommendation

The filing indicates a significant vote of confidence from a specialized institutional investor, Casdin Capital, which has increased its stake to 14.0% and expressed an intent to engage with management to maximize shareholder value. This is a positive signal, suggesting potential for strategic improvements or a belief in the company's undervalued assets. However, without additional financial or operational updates from BioLife Solutions, Inc., a 'hold' recommendation is prudent. Investors should monitor Casdin Capital's future actions and the company's performance, as this filing primarily reflects an ownership change rather than a direct operational catalyst.

Keywords

BioLife Solutions, Casdin Capital, Schedule 13D, Institutional Investment, Shareholder Activism, Common Stock, Biotechnology, Life Sciences, Investment Adviser, Equity Stake